Up and coming cell therapy companies to watch out for
Is the early stage cell therapy landscape bleak or promising these days? Perhaps it depends on which angle you look at the question.
Originally, I had planned to cover five preclinical cell therapy companies we hadn’t covered before, although this ended up as six with five intriguing ones, one I’m not a fan of, plus some additional really intriguing academic research in preclinical development, which may have some broader clinical applications many may have not realised yet.
We also highlight some emerging trends in this niche as early stage companies learn from what has gone before and begin to adapt their pipelines to address the challenges rather than merely be yet another me-too CD19 CAR whatever.
This inevitably means the emergence of new targets, modalities, technologies, and approaches…
To read our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
